IP Library Granted Patent US 12,351,797
Granted Patent B2
US 12,351,797 · App. 17/509,798 · Granted Jul 8, 2025

Adenovirus library and methods

Inventors: Masato Yamamoto (Minneapolis, MN); Yoshiaki Miura (Roseville, MN)
Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
C12N15/1034C12N15/1037C12N15/86C12N2710/10043C12N2710/10071C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,797
App. No.
17/509,798
Granted
Jul 8, 2025
Kind
B2
Abstract

Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.

Claims (14)

1. An adenovirus comprising an AB-loop comprising the amino acid sequence VTINRSA (SEQ ID NO: 12).

2. A method for delivering anti-tumor therapy to a subject, the method comprising:

administering to the subject the adenovirus of claim 1 ;

allowing the adenovirus to bind to a tumor cell that expresses mesothelin; and

allowing the adenovirus to infect the tumor cell, thereby delivering anti-tumor therapy.

3. The method of claim 2 , wherein the anti-tumor therapy comprises:

replicating the adenovirus; and

lysing the tumor cell.

4. The method of claim 2 , wherein the anti-tumor therapy comprises:

delivering a therapeutic polynucleotide to the tumor cell; and

allowing the tumor cell to express the therapeutic polynucleotide.

5. The method of claim 2 , wherein the tumor cell is a pancreatic tumor cell.

6. The method of claim 2 , wherein the tumor cell is a lung carcinoma cell.

7. The method of claim 2 , wherein the adenovirus is administered to the subject systemically.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 13, 2023
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065989/0224 →
Continuity (4)
Continuation 16250282 · Jan 17, 2019
Division 13447847 · Apr 16, 2012
Provisional Application 61475402 · Apr 14, 2011
Related Publication 20220042006A1 · Feb 10, 2022
References Cited (22)
US 6297004B1 · Russell · 2001 [cited by applicant]
US 10208304B2 · Yamamoto · 2019 [cited by examiner]
US 11162092B2 · Yamamoto · 2021 [cited by examiner]
US 20090074658A1 · Lupold · 2009 [cited by applicant]
US 20090098599A1 · VonSeggern · 2009 [cited by applicant]
Aoki et al., “Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro,” [cited by applicant]
Bewley, Maria C. et al 1999 [cited by applicant]
Graham et al. Methods for construction of adenovirus vectors. [cited by applicant]
Hassan et al. Mesothelin targeted cancer immunotherapy. European Journal of Cancer. vol. 44, pp. 46-53, 2008. [cited by applicant]
Hatanaka, Kazuteru et al., Jul. 2003 [cited by applicant]
Krasnykh, Vet al, 1996 [cited by applicant]
Lupold et al., “A novel method for generating and screening peptides and libraries displayed on adenovirus fiber,” [cited by applicant]
Miura et al., “Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob,” [cited by applicant]
Miura, Yoshiaki et al May 2009 Molecular Therapy vol. 17, Supplement 1: S321. [cited by applicant]
Miura et al., “Infectivity-selective Oncolytic Adenovirus Developed by High-throughput Screening of Adenovirus-formatted Library,” [cited by applicant]
Neylon, C. 2004 Nucleic Acids Research 32: 1448-1459. [cited by applicant]
Palmer et al., “Improved system for helper-dependent adenoviral vector production,” [cited by applicant]
Takayama et al. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. [cited by applicant]
Toth et al. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opinion on Biological Therapy. vol. 10, No. 3, pp. 353-368, 2010. [cited by applicant]
Tsuruta et al., “A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer,” [cited by applicant]
Von Seggern et al., “Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells,” [cited by applicant]
Wirth et al. Road to precision: recombinase-based targeting technologies for genome engineering. [cited by applicant]